OrbiMed Advisors reports $12.67 million Enliven Therapeutics common stock sale

Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc.

ELVN

0.00
  • OrbiMed Advisors, a more-than-10% owner of Enliven Therapeutics, disclosed sales of common stock on June 15, 2026.
  • OrbiMed Genesis Master Fund sold 9,086 shares at $45.02, cutting its stake to 245,728 shares.
  • OrbiMed Private Investments VII sold 272,322 shares at $45.02, reducing its holding to 7,388,902 shares.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000947871-26-000637), on June 17, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.